Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

461
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
461
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

2.6K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
2.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

49
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

6.1K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.1K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

167
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
167
Urea Cycle01:23

Urea Cycle

47.5K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
47.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-generation newborn screening: feasibility of combined genetic and biochemical testing for 95 treatable inherited metabolic disorders.

Metabolomics : Official journal of the Metabolomic Society·2026
Same author

Living with phenylketonuria in adulthood.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Management of acute metabolic decompensation in maple syrup urine disease: guidance based on international clinical practice.

Orphanet journal of rare diseases·2026
Same author

Vitamin B<sub>12</sub> Supplementation: Is More Always Better?

Nutrients·2026
Same author

Letter to the editor: Newborn screening for low blood citrulline leads to diagnosis of ornithine aminotransferase deficiency.

Molecular genetics and metabolism·2026
Same author

Effectiveness of Riboflavin in Inherited Metabolic Diseases: A Systematic Review.

Journal of inherited metabolic disease·2026

Related Experiment Video

Updated: Nov 5, 2025

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

3.6K

Phenylketonuria.

Francjan J van Spronsen1, Nenad Blau2, Cary Harding3

  • 1Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands. f.j.van.spronsen@umcg.nl.

Nature Reviews. Disease Primers
|May 21, 2021
PubMed
Summary
This summary is machine-generated.

Phenylketonuria (PKU) is a metabolic disorder causing brain dysfunction due to high phenylalanine levels. Current treatments like diet and medication have limitations, necessitating research into new therapies.

More Related Videos

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.7K
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.2K

Related Experiment Videos

Last Updated: Nov 5, 2025

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

3.6K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.7K
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.2K

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Phenylketonuria (PKU), or phenylalanine hydroxylase (PAH) deficiency, is an inherited metabolic disorder.
  • Elevated phenylalanine levels lead to significant brain dysfunction, including intellectual disability and epilepsy if untreated.
  • Newborn screening enables early diagnosis, but long-term neurocognitive outcomes can be suboptimal despite treatment.

Purpose of the Study:

  • To review the current understanding of PKU pathophysiology and treatment limitations.
  • To highlight the need for improved therapeutic strategies beyond traditional dietary management.
  • To discuss emerging treatments and the importance of continued research.

Main Methods:

  • Literature review of PKU pathophysiology, diagnosis, and treatment modalities.
  • Analysis of the efficacy and limitations of current therapies, including diet, tetrahydrobiopterin, and pegylated phenylalanine ammonia lyase.
  • Exploration of novel therapeutic approaches such as mRNA and gene therapy.

Main Results:

  • Dietary restriction is the primary treatment but adherence is challenging and outcomes are suboptimal.
  • Pharmacological treatments like tetrahydrobiopterin benefit only a subset of patients, and pegylated phenylalanine ammonia lyase has adverse effects.
  • The precise mechanisms of brain dysfunction in PKU are not fully understood.

Conclusions:

  • Despite decades of management, PKU treatment outcomes remain suboptimal, underscoring the need for better therapies.
  • Existing treatments have significant limitations, driving the development of innovative approaches like gene therapy.
  • Further research into PKU's pathophysiology is crucial for developing more effective, targeted treatments.